Key facts
- It has raised $48.0M; the latest was Later Stage VC ($18.1M) in Dec 2024.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Korea Development Bank, Johnson & Johnson Innovation - JLABS, Korea Technology Finance — 28 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Ubix Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Ubix Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ubix Therapeutics
Developer of protein degradation therapeutics designed to provide anti-cancer treatment. The company utilizes inhibitor technology that leverages the body's own natural protein degradation machinery to eliminate diseased proteins, thereby leading to near-complete inactivation of disease-causing pathways, enabling healthcare professionals to increase life span and improve quality of life for affected patients.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 41
- Website
- ubixtrx.com/
- Ownership
- Privately Held (backing)
Ubix Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ubix Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ubix Therapeutics in its N-PORT filings yet. We sweep new filings monthly.